Markets

Health Care Sector Update for 04/20/2015: CLDX, LGND, LLY

Top Health-care stocks:

JNJ: +0.5%

PFE: +0.3%

ABT: +0.4%

MRK: +1.0%

AMGN: +0.7%

Health-care shares were higher in pre-market trade Monday.

In health-care stocks news, Celldex Therapeutics ( CLDX ) said pre-clinical data supports the expansion of its varlilumab cancer treatment into combination studies with PD-1 inhibitors.

Shares in the company were trading 3.7% higher at $27.75 during pre-market trading . Over the past 52 weeks, the company has traded between $10.76 and $32.82.

Meanwhile, Eli Lilly and Company ( LLY ) said it met the primary endpoint in its Phase 3 study of ixekizumab in patients with active psoriatic arthritis. The drug was found to be statistically superior to placebo, the company said.

Shares in the company were unchanged at $72.47 during pre-market trading. Over the past 52 weeks, the company has traded between $57.35 and $77.46.

And Ligand Pharmaceuticals ( LGND ) presented promising pre-clinical data on single agent and combination activity of two of its partner TG Therapeutics' ( TGTX ) IRAK4 inhibitor compounds.

Shares in the company were unchanged at $85.85 during pre-market trading. Over the past 52 weeks, the company has traded between $41.99 and $87.17.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CLDX LGND LLY TGTX

Other Topics

Commodities

Latest Markets Videos